Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors —protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)
This study addresses the current gap in the evidence base regarding the combination of these two drugs, which is particularly relevant given the American Diabetes Association and European Association for the Study of Diabetes guidelines recommending their combined use for patients with obesity, type 2 diabetes, and chronic kidney disease who do not achieve metabolic control with either drug alone.Trial registrationClinicalTrials.gov Identifier: NCT05390307 Trial registration date - 25th May 2022
Source: Trials - Category: Research Source Type: clinical trials
More News: Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Medical Ethics | Obesity | Research | Sodium | Study | Urology & Nephrology | Weight Loss